ECSP20060179A - Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro - Google Patents

Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro

Info

Publication number
ECSP20060179A
ECSP20060179A ECSENADI202060179A ECDI202060179A ECSP20060179A EC SP20060179 A ECSP20060179 A EC SP20060179A EC SENADI202060179 A ECSENADI202060179 A EC SENADI202060179A EC DI202060179 A ECDI202060179 A EC DI202060179A EC SP20060179 A ECSP20060179 A EC SP20060179A
Authority
EC
Ecuador
Prior art keywords
bupropion
dosage forms
enantiomerically enriched
methods
pure bupropion
Prior art date
Application number
ECSENADI202060179A
Other languages
English (en)
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of ECSP20060179A publication Critical patent/ECSP20060179A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ECSENADI202060179A 2018-02-23 2020-09-23 Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro ECSP20060179A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US201962809480P 2019-02-22 2019-02-22

Publications (1)

Publication Number Publication Date
ECSP20060179A true ECSP20060179A (es) 2020-12-31

Family

ID=67688503

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202060179A ECSP20060179A (es) 2018-02-23 2020-09-23 Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro

Country Status (19)

Country Link
EP (1) EP3755312A4 (enrdf_load_stackoverflow)
JP (3) JP2021513998A (enrdf_load_stackoverflow)
KR (3) KR20230075531A (enrdf_load_stackoverflow)
CN (1) CN112087999A (enrdf_load_stackoverflow)
AU (3) AU2019223187B2 (enrdf_load_stackoverflow)
BR (1) BR112020017179A2 (enrdf_load_stackoverflow)
CA (1) CA3092076A1 (enrdf_load_stackoverflow)
CL (1) CL2020002166A1 (enrdf_load_stackoverflow)
CR (1) CR20200415A (enrdf_load_stackoverflow)
EC (1) ECSP20060179A (enrdf_load_stackoverflow)
IL (2) IL313368A (enrdf_load_stackoverflow)
MA (1) MA51914A (enrdf_load_stackoverflow)
MX (2) MX2020008704A (enrdf_load_stackoverflow)
MY (1) MY202993A (enrdf_load_stackoverflow)
NI (1) NI202000056A (enrdf_load_stackoverflow)
NZ (1) NZ767378A (enrdf_load_stackoverflow)
PE (1) PE20211752A1 (enrdf_load_stackoverflow)
SG (1) SG11202008056SA (enrdf_load_stackoverflow)
WO (1) WO2019165379A1 (enrdf_load_stackoverflow)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2021055124A1 (en) * 2019-09-20 2021-03-25 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318960A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
DE60330909D1 (de) * 2003-08-08 2010-02-25 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
IL313368A (en) * 2018-02-23 2024-08-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
CA3092076A1 (en) 2019-08-29
KR20240091043A (ko) 2024-06-21
IL276871A (en) 2020-10-29
EP3755312A1 (en) 2020-12-30
BR112020017179A2 (pt) 2020-12-22
CR20200415A (es) 2021-02-03
NZ767378A (en) 2024-03-22
MX2023009281A (es) 2023-08-17
MY202993A (en) 2024-05-31
JP2024075655A (ja) 2024-06-04
AU2022204521A1 (en) 2022-07-21
CL2020002166A1 (es) 2020-10-23
MA51914A (fr) 2020-12-30
SG11202008056SA (en) 2020-09-29
IL276871B1 (en) 2024-07-01
KR20230075531A (ko) 2023-05-31
JP2021513998A (ja) 2021-06-03
AU2019223187A1 (en) 2020-09-17
WO2019165379A1 (en) 2019-08-29
AU2022204521B2 (en) 2024-09-05
AU2024205858A1 (en) 2024-09-05
IL313368A (en) 2024-08-01
EP3755312A4 (en) 2022-03-16
JP2022153638A (ja) 2022-10-12
MX2020008704A (es) 2020-12-07
CN112087999A (zh) 2020-12-15
KR20210003091A (ko) 2021-01-11
AU2019223187B2 (en) 2022-07-28
NI202000056A (es) 2021-01-11
PE20211752A1 (es) 2021-09-06
IL276871B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
ECSP20060179A (es) Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro
MX2016010235A (es) Composicion farmaceutica que comprende eritrocitos que encapsulan una enzima dependiente de fosfato de piridoxal (plp) y su cofactor.
UY36703A (es) Composiciones y métodos para la administración de un polinucleótido en una planta
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
UY32388A (es) Composicion farmaceutica sólida que comprende amlodipina y losartan con estabilidad mejorada
ECSP18015616A (es) Tableta
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
WO2020061486A3 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
MX394496B (es) Administracion de metabolitos de berberina
MX2016006318A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
UY29845A1 (es) Forma de dosificación osmótica con aspectos de liberación controlada y de liberación rápida
CL2021001636A1 (es) Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida
MX2022004449A (es) Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia.
MX381450B (es) Un medicamento combinado que comprende fenilefrina y paracetamol
AR097590A1 (es) Métodos para tratar el síndrome del x frágil y trastornos relacionados
ECSP22030119A (es) Formas de dosificación y métodos para bupropión enantioméricamente enriquecido o puro
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo
MX2018010367A (es) Titulacion de cebranopadol.
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
HK40068404A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40066587A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
Hwang et al. Review of the work of Ji-Young Hwang
HK40041795A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
AR104877A1 (es) Composiciones y métodos para la administración de un polinucleótido en una planta